Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomlinson, J. W.
Right arrow Articles by Close, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomlinson, J. W.
Right arrow Articles by Close, C. F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 26:1802-1805, 2003
© 2003 by the American Diabetes Association, Inc.

Epidemiology/Health Services/Psychosocial Research
Original Article

Treating Hypertension in Diabetic Nephropathy

Jeremy W. Tomlinson, MRCP, Katharine R. Owen, MRCP and Colin F. Close, MD

From the Department of Diabetes, Taunton and Somerset Hospital, Taunton, U.K.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
OBJECTIVE—Control of hypertension in patients with diabetic nephropathy improves mortality and slows progression to end-stage renal disease. However, blood pressure is difficult to treat; multiple drug combination therapy is required and treatment algorithms to establish this are lacking. We used a stepped-care algorithm, centered on maximum doses of an ACE inhibitor or angiotensin II receptor blocker, to treat hypertension according to American Diabetes Association recommended blood pressure target goals (<130/80 mmHg) in patients with diabetic nephropathy.

RESEARCH DESIGN AND METHODS—We treated 49 consecutive patients with diabetes (13 with type 1 and 36 with type 2), diabetic nephropathy, and proteinuria >=500 mg/24 h with a stepped-care blood pressure treatment algorithm. The level of blood pressure control achieved at most recent follow-up was assessed.

RESULTS—Patients were followed for a median of 18 months (range 9–48). Mean blood pressure achieved was 140/75 ± 23/14 mmHg in patients with type 1 diabetes and 146/76 ± 22/14 mmHg in patients with type 2 diabetes. Target blood pressure was reached in 16 (33%) patients, 6 of 13 patients with type 1 diabetes and 10 of 36 patients with type 2 diabetes, whereas systolic blood pressure remained above the target level in the remaining patients. There was no difference in baseline blood pressure, proteinuria, or serum creatinine level between patients who were treated to target and those who were not.

CONCLUSIONS—Levels of blood pressure control similar to those achieved in clinical trials in diabetic nephropathy were obtained with a stepped-care algorithm. However, in most patients, systolic blood pressure was difficult to control to target despite the use of multiple drug combination therapy.

Abbreviations: ARB, angiotensin II receptor blocker


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
Hypertension is a major risk factor for cardiovascular morbidity and mortality in patients with diabetes (1,2). Diabetic nephropathy develops in up to 40% of patients with type 1 diabetes (3) and 35% of patients with type 2 diabetes (4), and rigorous treatment of hypertension slows the rate of decrease in renal function and improves mortality (5,6). Few studies have addressed whether recommended targets for blood pressure control (7,8) can be achieved in everyday clinical practice, and although multiple drug combination therapy is needed to treat hypertension in most patients with nephropathy, treatment algorithms for establishing this are lacking and the optimum drug combination remains uncertain. After review of the evidence available in 1998 (7,9–18), we devised a stepped-care algorithm for treating hypertension in diabetic nephropathy and evaluated its ability to treat hypertension to American Diabetes Association recommended blood pressure target goals (8) in consecutive patients with diabetic nephropathy attending a hospital diabetes clinic.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
We applied a stepped-care algorithm (Fig. 1) for treating hypertension to 49 consecutive white European patients with overt diabetic nephropathy, defined as persistent proteinuria >=500 mg/24 h and with no evidence of other kidney disease, renal tract disease, or heart failure, attending a hospital diabetes clinic in the U.K. All community patients with proteinuria are routinely referred from primary care to the hospital clinic for further management (local referral guideline). The stepped-care algorithm involved the sequential addition and titration of antihypertensive drugs to maximum tolerated doses until target blood pressure was achieved and/or maintained. The principle of once-daily dosing of each drug class was used to enhance patient adherence (19). Blockade of the renin-angiotensin system, first demonstrated with ACE inhibition in 1993 (9), confirmed many times since that time (10), and recently extended to include the angiotensin II receptor blocker (ARB) class (11,12) is the accepted cornerstone of treatment in diabetic nephropathy. Therefore, maximum doses of either ACE inhibitor (corresponding to 40 mg enalapril/lisinopril or ramipril 10 mg) or ARB (corresponding to losartan 150 mg or irbesartan 300 mg) in the event of ACE inhibitor–associated cough were used routinely in the stepped-care algorithm. ACE inhibition was induced in steps over a 4-week period before the addition of a diuretic at 6 weeks. Although there is uncertainty regarding the long-term effects of other drug classes (13,17,18), in patients with type 2 diabetes and nephropathy, nondihydropyridine calcium channel blockers (diltiazem and verapamil) seem to possess renoprotective properties broadly equivalent to those of ACE inhibitors and exert a synergistic effect when used in combination with them (18,20). A drug from this class was therefore used routinely in all patients who were unable to continue treatment with an ACE inhibitor or ARB.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 1— Stepped-care algorithm for treatment of hypertension in diabetic nephropathy.

 
Office blood pressure was measured and recorded by one of three observers at each clinic visit according to the recommendations of the British Hypertension Society (21). Treatment targets were systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg (8). The interval between clinic visits was determined on an individual case basis, according to current blood pressure level and response, but was at least every 3 months and usually every 6 weeks during dose-titration phases. At each clinic visit, patients were also provided with clear written instructions, where necessary, for the titration/addition of drug therapies between clinic visits by their primary care teams to optimize therapy. Details of antihypertensive drugs used and withdrawn because of adverse effects were routinely recorded at each visit. ACE inhibitor/ARB therapy was withdrawn if hyperkalemia developed, defined as a sustained serum potassium level >6.0 mmol/l, despite concurrent thiazide or loop diuretic therapy and avoidance of other drugs impairing potassium excretion (nonsteroidal anti-inflammatory drugs, potassium-sparing diuretics) or dietary potassium supplementation (Losalt, a salt substitute), or if worsening renal impairment developed, defined as a sustained increase in serum creatinine level >=30% over 3 months (22). All patients were also treated with aspirin and a statin if total cholesterol level exceeded 5.0 mmol/l. Patient case notes and computerized hospital pathology records were scrutinized in a retrospective analysis and data were extracted at initial presentation of nephropathy (baseline) and at the most recent clinic attendance (follow-up).

Comparisons of demographic and blood pressure data that followed a normal distribution were examined by Student’s t test. For all other comparisons, Mann-Whitney U test was used. Differences in proportions were examined by Fisher’s exact test.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
In all 49 patients, blood pressure was above target at baseline (Table 1) and mean ± SD blood pressure in the entire cohort was 168/88 ± 28/16 mmHg. Patients were followed for a median of 18 months (range 9–48). Blood pressure at most recent follow-up was similar in patients with type 1 diabetes (140/75 ± 23/14 mmHg) and type 2 diabetes (146/76 ± 22/14 mmHg). Target blood pressure was achieved in 16 patients (33%): 6 of 13 patients with type 1 diabetes and 10 of 36 patients with type 2 diabetes. Target diastolic blood pressure, with systolic blood pressure remaining above target, was reached in an additional 24 patients (29%), but in the remaining 9 patients (18%), adequate control of either systolic or diastolic blood pressure was impossible despite multiple drug combination therapy. There were no differences between patients treated to target and those who were not in baseline systolic blood pressure (172 ± 31 vs. 168 ± 28 mmHg; P = 0.69), diastolic blood pressure (92 ± 17 vs. 87 ± 17 mmHg; P = 0.31), or proteinuria (1,820 vs. 2,080 mg/24 h; P = 0.27). During follow-up, end-stage renal disease developed in two patients, in whom renal replacement therapy was initiated, and eight patients died. Of the patients who died, blood pressure was controlled in two patients, diastolic blood pressure only was controlled in three patients, and neither systolic nor diastolic blood pressure was controlled in three patients. More patients with type 1 diabetes (6 of 13) than with type 2 diabetes (10 of 36) were treated to the target blood pressure goal; however, this difference was not statistically significant.


View this table:
[in this window]
[in a new window]
  		Table 1— Baseline clinical characteristics of the patients

 
One patient with severe widespread atherosclerotic vascular disease, bilateral renal bruits, and renal impairment was not treated initially with an ACE inhibitor or ARB. These drugs had to be discontinued in an additional 12 patients: 5 with sustained hyperkalemia, 3 with worsening renal impairment, and 1 with intractable cough. All patients with treatment resistance (blood pressure >160/90 mmHg) despite three synergistic agents at full dosage were evaluated for secondary hypertension. The three patients with worsening renal impairment on ACE inhibitor/ARB therapy were all evaluated for underlying renovascular disease, although no lesions amenable to angioplasty or stent insertion were identified.

In patients who continued treatment with an ACE inhibitor or ARB, follow-up systolic blood pressure (145 ± 22 vs. 145 ± 22 mmHg, P = 0.01) and diastolic blood pressure (78 ± 13 vs. 71 ± 14 mmHg, P = 0.15) was not different from patients in whom the drug was withdrawn. The median number of drug classes used in both type 1 and type 2 diabetes was 3 (range 1–5).

A total of 16 patients (24%) experienced an AE sufficient to necessitate withdrawal of one or more (range 1–3) antihypertensive drugs. A total of 23 individual drug withdrawals occurred; two resulted from a severe interaction between a ß-blocker and diltiazem (bradycardia necessitating hospital admission), two resulted from diuretic intolerance (one thiazide, one loop), and one each resulted from intolerance to ß-blocker (fatigue), dihydropyridine CCB (amlodipine; edema), nondihydropyridine CCB (verapamil), moxonidine (dizziness), hydralazine, and minoxidil (edema).

Patients with type 2 diabetes were older (61 ± 11 vs. 42 ± 13 years; P < 0.001) and more obese (BMI 31 vs. 27 kg/m2; P = 0.04) than those with type 1 diabetes and were also significantly more hypertensive, with both higher systolic pressure (174 vs. 154 mmHg; P = 0.02) and diastolic pressure (92 vs. 77 mmHg; P = 0.003) at baseline (Table 1). Glycemic control was significantly better in patients with type 2 diabetes than those with type 1 diabetes (HbA1c 7.1 vs. 9.4%; P = 0.005), but there were no significant differences in baseline proteinuria (P = 0.80), serum creatinine level (P = 0.73), or serum cholesterol level (P = 0.35) (Table 1).


   CONCLUSIONS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
Achieved levels of blood pressure reported in the large-scale clinical trials in diabetic nephropathy have ranged between 128–134/77–82 (9) and 140–144/77 mmHg (11,12). Although similar levels were obtained in patients with both type 1 and type 2 diabetes with the stepped-care algorithm, differences in ethnic background between the patients in this study, an exclusively white European population, and the more heterogeneous populations in the clinical trials may influence direct comparison, particularly if blood pressure is more difficult to control in nonwhite patients. However, the target blood pressure goals remained difficult to reach in many patients, particularly those with type 2 diabetes, and blood pressure was controlled to target in only one third of patients. Systolic blood pressure was more difficult to control. The stepped-care algorithm achieved blood pressure control similar to that reported in clinical practice from another diabetes clinic in the U.K. (mean ± SD blood pressure 146/72 ± 23/14 mmHg) (23) and better than that reported (mean blood pressure 159/85 mmHg) at referral to a U.K. specialist renal clinic (24). Greater difficulty in treating patients to target may be a feature of patients with diabetes (25), and achieved blood pressure levels in clinical trials of diabetic nephropathy were consistently higher than those reported in similar trials of nondiabetic renal disease (5,14,15). It has been suggested that tight control of hypertension may exert a greater impact on the progression of chronic nephropathies than the renoprotective properties of individual antihypertensive drug classes (7,13–16); however, when blood pressure exceeds 125/75 mmHg, renoprotection seems to exert clinical influence.

The association between hypertension and obesity is well recognized (26). This may contribute to the greater difficulty experienced in treating hypertension in nephropathy in type 2 diabetes and suggests that more aggressive treatment strategies will be needed (27). A surprisingly high rate of hyperkalemia was seen in this study, which is unexplained, although higher doses of ACE inhibitor/ARB were used than in some earlier studies. Pooled data from clinical trials suggest a hyperkalemia rate <2% with ACE inhibitor/ARB treatment (9,12,14), similar to that seen with regimens not using that strategy (28). Although dual blockade of the renin-angiotensin system may further lower blood pressure in treatment-resistant hypertension in type 2 diabetes (29), lower doses (underdosing) of ACE inhibitor were used than in this study and the benefits of the addition of ARB to maximum doses of ACE inhibitor remain unknown.

The use of once-daily dosing schedules should have optimized compliance. Although not assessed in this study, compliance may, in fact, not be a significant contributor to treatment resistance (30). There were a number of treatment failures due to adverse effects with the various antihypertensive drug classes used in the algorithm, which may contribute toward treatment resistance by restricting treatment options.

In everyday clinical practice, blood pressure is often difficult to control in diabetic nephropathy, but a stepped-care approach can achieve a similar degree of control to that reported in the clinical trials. A treatment target <130/80 mmHg (8) is difficult to reach in many patients, and more stringent targets (7,31) may be even less achievable in the majority of patients.


   Footnotes
 
Address correspondence and reprint requests to Dr. Colin F Close, Department of Diabetes, Taunton and Somerset Hospital, Taunton TA1 5DA, U.K. E-mail: colin.close{at}tst.nhs.uk.

Received for publication 25 September 2002 and accepted in revised form 22 February 2003.

C.F.C. has received honoraria or consulting fees from Pfizer, MSD, BMS, Aventis Pharma, and Sanofi-Synthelabo.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.


   References
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Hypertension in Diabetes Study (HDS): increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 11:319–325, 1993[Medline]
  2. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762, 1998[Medline]
  3. Krolewski AS, Warram JH, Christlieb A, Busick RJ, Kahn CR: The changing natural history of nephropathy in type 1 diabetes. Am J Med 78:785–794, 1985
  4. Mehler PS, Jeffers BW, Estacio R, Schrier RW: Association of hypertension and complications in non-insulin dependent diabetes mellitus. Am J Hypertens 10:152–161, 1997[Medline]
  5. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294:1443–1452, 1987
  6. Parving H, Hommel E: Prognosis in diabetic nephropathy. BMJ 299:230–233, 1989
  7. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C, for the Modification of Diet in Renal Disease Study Group: Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 29:641–650, 1997[Abstract/Free Full Text]
  8. American Diabetes Association: ADA Position Statement: diabetic nephropathy. Diabetes Care 21:S50–S53, 1998
  9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462, 1993[Abstract/Free Full Text]
  10. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney disease with diabetes: a meta-regression analysis. Ann Intern Med 118:129–138, 1993[Abstract/Free Full Text]
  11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860, 2001[Abstract/Free Full Text]
  12. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snappin SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869, 2001[Abstract/Free Full Text]
  13. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 10:39–45, 1995[Abstract/Free Full Text]
  14. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945, 1996[Abstract/Free Full Text]
  15. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863, 1997[Medline]
  16. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy: Collaborative Study Group. Am J Kidney Dis 34:951–954, 1999[Medline]
  17. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352:1252–1256, 1998[Medline]
  18. Bakris G, Copley B, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641–1650, 1996[Medline]
  19. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881–1884, 1990[Abstract]
  20. Bakris G, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54:1283–1289, 1998[Medline]
  21. O’Brien E, Petrie JC, Littler WA, De Swiet M, Padfield PD, Dillon MJ: Blood Pressure Measurement: Recommendations of the British Hypertension Society. 3rd ed. London, BMJ Publishing Group, 1997
  22. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this cause for concern. Arch Intern Med 160:685–693, 2000[Abstract/Free Full Text]
  23. Wahid ST, Baines LA, Savopoulos L, Connolly VM, Kelly WF, Bilous RW: Longitudinal analysis of blood pressure, lipid and glycaemic control in diabetic patients with nephropathy attending a hospital outpatient clinic and their relationship to renal function, mortality and cardiovascular morbidity. Diabetes Care 24:789–790, 2001[Free Full Text]
  24. Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM: Diabetic nephropathy: how effective is treatment in clinical practice? Q J Med 95:41–49, 2002
  25. Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, Ruilope LM: Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 35:1038–1042, 2000[Abstract/Free Full Text]
  26. Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE, Colditz GA: Body weight, weight change and risk of hypertension in women. Ann Intern Med 128:81–88, 1998[Abstract/Free Full Text]
  27. Bakris GL, Weir MR, Sowers JR: Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med 101:33S–46S, 1996
  28. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357:1801–1808, 2001
  29. Rossing K, Christensen PK, Jensen BR, Parving H-H: Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetes Care 25:95–100, 2002[Abstract/Free Full Text]
  30. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E: Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ 323:142–146, 2001[Abstract/Free Full Text]
  31. Mailloux LU, Levey AJ: Hypertension in chronic renal disease. Am J Kidney Dis 32: S120–S141, 1998

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. Kumar and P. H Winocour
Review: Dual blockade of the renin angiotensin system in diabetes -- rationale and risks
The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 266 - 271.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
A. F. Rubio-Guerra, A. Arceo-Navarro, G. Vargas-Ayala, L. Rodriguez-Lopez, J. J. Lozano-Nuevo, and C. T. Gomez-Harper
The Effect of Trandolapril and Its Fixed-Dose Combination With Verapamil on Proteinuria in Normotensive Adults With Type 2 Diabetes
Diabetes Care, July 1, 2004; 27(7): 1688 - 1691.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomlinson, J. W.
Right arrow Articles by Close, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomlinson, J. W.
Right arrow Articles by Close, C. F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum